ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    A

    Dr Anew Kuykendall, MD

    Medical professional dedicated to sharing knowledge and insights through educational videos.

    Dr. Andrew Kuykendall describes the safety and tolerability of avapritinib in AdvSM(Video 3/3)

    Dr. Andrew Kuykendall describes the safety and tolerability of avapritinib in AdvSM(Video 3/3)

    Avapritinib in AdvSM - Safety

    Andrew Kuykendall, MD
    Hematological Malignancies
    Dr. Andrew Kuykendall reviews the efficacy outcomes of avapritinib in AdvSM (Video 2/3)

    Dr. Andrew Kuykendall reviews the efficacy outcomes of avapritinib in AdvSM (Video 2/3)

    Avapritinib in AdvSM - Efficacy

    Andrew Kuykendall, MD
    Hematological Malignancies
    Dr. Andrew Kuykendall discusses study design and patient population of avapritinib in AdvSM (Video 1/3)

    Dr. Andrew Kuykendall discusses study design and patient population of avapritinib in AdvSM (Video 1/3)

    Avapritinib in AdvSM – Patient population

    Andrew Kuykendall, MD
    Hematological Malignancies
    Dr. Andrew Kuykendall discusses disease modifying properties of interferon and defines how ropeginterferon is different from traditional interferon in terms of dosing and tolerability. (Video 3/3)

    Dr. Andrew Kuykendall discusses disease modifying properties of interferon and defines how ropeginterferon is different from traditional interferon in terms of dosing and tolerability. (Video 3/3)

    Safety/Tolerability- How is ropeg different than regular interferon

    Andrew Kuykendall, M.D.
    ASCO Updates
    Hematological Malignancies
    +1 more
    Dr. Andrew Kuykendall discusses CYTOPV in the context of PROUD/CONTI PV and the goals of therapy in Polycythemia Vera (Video 2/3)

    Dr. Andrew Kuykendall discusses CYTOPV in the context of PROUD/CONTI PV and the goals of therapy in Polycythemia Vera (Video 2/3)

    CYTOPV in the context of PROUD/CONTI and goals of therapy in PV

    Andrew Kuykendall, M.D.
    ASCO Updates
    Hematological Malignancies
    +1 more
    Dr. Andrew Kuykendall discusses a high-level overview of the LOW-PV trial and the updated NCCN guidelines for low-risk Polycythemia Vera. (Video 1/3)

    Dr. Andrew Kuykendall discusses a high-level overview of the LOW-PV trial and the updated NCCN guidelines for low-risk Polycythemia Vera. (Video 1/3)

    LOW-PV Trial summary and Updates to NCCN guidelines for Low-risk PV

    Andrew Kuykendall, M.D.
    ASCO Updates
    Hematological Malignancies
    +1 more
    Dr. Andrew Kuykendall discusses the safety data from the PIONEER trial in indolent systemic mastocytosis (video 3/3)

    Dr. Andrew Kuykendall discusses the safety data from the PIONEER trial in indolent systemic mastocytosis (video 3/3)

    PIONEER-Safety

    Andrew Kuykendall, M.D.
    Hematological Malignancies
    Dr. Andrew Kuykendall discusses key efficacy outcomes from the PIONEER trial in indolent systemic mastocytosis (video 2/3)

    Dr. Andrew Kuykendall discusses key efficacy outcomes from the PIONEER trial in indolent systemic mastocytosis (video 2/3)

    PIONEER- Efficacy

    Andrew Kuykendall, M.D.
    Hematological Malignancies
    Dr. Andrew Kuykendall discussed diagnosing systemic mastocytosis (video 1/3)

    Dr. Andrew Kuykendall discussed diagnosing systemic mastocytosis (video 1/3)

    PIONEER- Diagnosing SM

    Andrew Kuykendall, M.D.
    Hematological Malignancies